Dr. Amy AbernethyOvjeren akaunt

@DrAbernethyFDA

Principal Deputy Commissioner and Acting CIO at

Vrijeme pridruživanja: ožujak 2019.

Medijski sadržaj

  1. Addressing rare diseases is a priority. Our Office of Orphan Products Development has an incredible technology modernization effort underway to streamline orphan drug designation requests.

    Prikaži ovu nit
  2. Medical extended reality is growing and we want to hear from you on best evaluation practices in virtual reality and augmented reality in medicine. Join us at our public workshop on March 5 and share your expertise

    Prikaži ovu nit
  3. As part of the at , I had the chance to talk to about all the great ways we are looking to improve our data strategy at FDA.

  4. : We announced a public meeting on Modernizing FDA’s Data Strategy today!

    Prikaži ovu nit
  5. Thanks to for hosting today’s chat with me at . We had a great conversation on how FDA is working to modernize our data strategy.

    Prikaži ovu nit
  6. In just a few minutes, I'll be participating in a Q&A at for the . I'm excited to be here, and I hope to see you there! Follow live coverage of the event at .

  7. Late yesterday, we announced the first FDA-approved vaccine for prevention of Ebola virus - a significant public health achievement, that will help protect against Ebola as well as advance U.S. government preparedness efforts.

    Prikaži ovu nit
  8. Today, FDA issued a draft guidance to provide some clarity regarding evidence needed to demonstrate effectiveness for drugs and biologics.

  9. Have you seen our new CURE ID app? It’s where health care professionals can report on novel uses of existing medicines for patients with difficult-to-treat infectious diseases, making it easier to spot promising new uses for existing drugs.

  10. We want to hear from you on the use of artificial intelligence (AI) in radiological imaging. Join the FDA at a public workshop on the evolving role of AI in radiological imaging Feb. 25-26, 2020 and comment on the open docket on .

    Prikaži ovu nit
  11. Had a great convo with at about the great work we are doing , including actions we’re taking to advance the technology we use to fulfill our public health mission as part of our Technology Modernization Action Plan.

    Prikaži ovu nit
  12. FDA took another step today to help people living with sickle cell disease by approving the first targeted therapy to treat patients with a painful complication of this deadly blood disorder.

  13. FDA’s approval of a new drug to treat complicated urinary tract infections represents another step forward in our efforts to ensure safe and effective drugs are available for treating antimicrobial resistant infections.

  14. As a public health agency, is keenly aware of the threat of drug resistant infections & we’re focused on facilitating the development of safe and effective new treatments to give patients more options to fight life-threatening infections.

    Prikaži ovu nit
  15. FDA today took another significant step in protecting women’s health by helping to ensure patients have complete information about the benefits & risks of breast implants. In a draft guidance we are providing proposed labeling recommendations.

    Prikaži ovu nit
  16. I enjoyed speaking with Susan Saulny yesterday at the event. We had a great discussion about how the FDA is focused on innovation to protect the public health as well as how we’re increasing access to cutting-edge treatments.

  17. Today, FDA informed patients, health care professionals, health care IT staff & manufacturers about cybersecurity vulnerabilities, known as URGENT/11, that — if exploited by a remote attacker — may introduce risks for medical devices and hospital networks.

    Prikaži ovu nit
  18. FDA is committed to incorporating the patient voice in drug development. Today we issued a draft guidance on patient focused drug development, which focuses on methods to identify what matters most to patients regarding their disease & treatment

    Prikaži ovu nit
  19. Today FDA released a suite of guidances to continue to encourage innovative approaches to the development of digital health tools, and to ensure the agency’s approach to overseeing these technologies advances along with it

    Prikaži ovu nit
  20. 1 Modernizing operations helps us perform effectively in an environment of rapidly evolving science, changing expectations & new responsibilities. The New Drugs Regulatory Program structure allows us to better meet modern realities of new drug review.

    Prikaži ovu nit

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·